Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP + levosimendan for acute heart failure
ChiCTR2600122263Phase 4Not yet recruiting
- Sponsor
- Meizhou People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of nesiritide and levosimendan in heart failure (HF), Acute Heart Failure (AHF) and chronic heart failure (CHF) (2 arms), sponsored by Meizhou People's Hospital. Primary endpoints: Left ventricular ejection fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
nesiritidelevosimendan
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)chronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR2600122263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122263.